Advanced ER+, HER2-Negative Breast Cancer

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Stemline Therapeutics
1 program
1
ElacestrantPhase 11 trial
Active Trials
NCT02338349Completed57Est. Apr 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Stemline TherapeuticsElacestrant

Clinical Trials (1)

Total enrollment: 57 patients across 1 trials

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Start: Jan 2015Est. completion: Apr 202057 patients
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space